JY
SLN

Jeff Yass’s Silence Therapeutics SLN Stock Holding History

Jeff Yass’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
19,400
+500
+3% +$3.52K ﹤0.01% 11809
2026
Q1 		$99.6K Buy
+18,900
New +$104K ﹤0.01% 12346

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Jeff Yass's SLN Position: Q2 2026 in Review

Jeff Yass increased its Silence Therapeutics (SLN) stake by 60% in Q2 2026, buying an estimated $487K and bringing the position to 184,519 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #6460.

Jeff Yass first reported a position in SLN in Q2 2025 and has held it in 4 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Jeff Yass held 184,519 shares of Silence Therapeutics worth $2.03M as of Q2 2026.
  • Jeff Yass bought 69,238 Silence Therapeutics shares in Q2 2026, an estimated $487K.
  • Silence Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6460 holding.
  • Jeff Yass first reported a position in Silence Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.